Recursion Pharmaceuticals Inc (RXRX) — Cash Flow-to-Debt Ratio
Recursion Pharmaceuticals Inc (RXRX) has a Cash Flow-to-Debt Ratio of -0.26x as of March 2026, meaning its operating cash flow of $-81.10 Million could theoretically repay 0% of its total liabilities ($314.75 Million) in one year. See RXRX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Recursion Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Recursion Pharmaceuticals Inc across 7 annual periods. Also explore Recursion Pharmaceuticals Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Recursion Pharmaceuticals Inc (2019–2025)
Year-by-year debt coverage analysis for Recursion Pharmaceuticals Inc. For market capitalisation and broader financial context, see RXRX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.08x | $-371.81 Million | $343.26 Million | ▼ -24.8% |
| 2024 | -0.87x | $-359.17 Million | $413.82 Million | ▲ +42.6% |
| 2023 | -1.51x | $-287.78 Million | $190.26 Million | ▼ -290.2% |
| 2022 | -0.39x | $-83.52 Million | $215.48 Million | ▲ +83.5% |
| 2021 | -2.35x | $-158.61 Million | $67.41 Million | ▼ -2516.8% |
| 2020 | -0.09x | $-45.40 Million | $504.87 Million | ▲ +64.4% |
| 2019 | -0.25x | $-57.04 Million | $225.70 Million | — |